Drug Trial Radar · NCT00000859
A Randomized Trial of the Efficacy and Safety of a Strategy of Starting With Nelfinavir Versus Ritonavir Added to Background Antiretroviral (AR) Nucleoside Therapy in HIV-Infected Individuals With CD4+ Cell Counts Less Than or Equal to 200/mm3
Last checked: Nov 19, 2026Latest source record: Oct 29, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,300
Actual
Start
Not stated
Primary completion
Not stated
Study completion Dec 2001
Sponsor
- Sponsor type
- NIH
- First posted
- Aug 31, 2001
Design
- Study type
- Interventional
- Phase
- Not applicable
- Model
- Parallel
- Primary purpose
- Treatment
- Who can join
- All sexes, from 13 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare nelfinavir (NFV) with ritonavir (RTV) for delaying disease progression or death in HIV-infected patients with CD4+ cell counts less than 100 cells/mm3 \[AS PER AMENDMENT 3/11/98: less than or equal to 200 cells/mm3\]. To compare NFV with RTV for the development of adverse events and for rates of permanent discontinuation of study medication. \[AS PER AMENDMENT 10/02/97: To compare by intention-to-treat analysis for disease progression, including death, the following two regimens: NFV plus background combination antiretroviral (AR) therapy followed by indinavir (IDV) or RTV in the event of significant intolerance; and RTV plus AR therapy followed by IDV, then NFV, in the event of significant intolerance.\] \[AS PER AMENDMENT 3/11/98: SUBSTUDY CPCRA 045: To determine the relative rates of emergence of HIV-1 resistance and to compare changes in plasma HIV RNA levels and CD4+ cell counts in a sample of patients with CD4+ cell counts \<= 200/mm3 who are enrolled in protocol CPCRA 042.\] AR therapy is rapidly becoming the standard of care for the treatment of HIV infection. AR therapy provides the best opportunity for maximizing viral suppression, reducing toxicity and delaying the emergence of resistant strains. The newest class of AR agents, the HIV protease inhibitors, exhibits the most potent anti-HIV effects described to date. This study will compare 2 protease inhibitors, NFV and RTV for efficacy and safety in a population with advanced HIV disease, who are taking various background nucleoside therapies.
Conditions
- HIV Infections
Interventions
Indinavir sulfateDrug
RitonavirDrug
Nelfinavir mesylateDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
44 sites in 2 countries. Site status is shown where the registry gives one.
Community Consortium / UCSF
San Francisco, California
Community Consortium of San Francisco
San Francisco, California
Denver Community Program for Clinical Research on AIDS
Denver, Colorado
Denver CPCRA / Denver Pub Hlth / Rocky Mt Cancer Ctr Aurora
Denver, Colorado
Denver CPCRA / Denver Public Hlth
Denver, Colorado
Infectious Disease Physicians / Northern Virginia
Washington D.C., District of Columbia
Timothy A Price
Washington D.C., District of Columbia
Veterans Administration Med Ctr / Regional AIDS Program
Washington D.C., District of Columbia
Washington Reg AIDS Prog / Dept of Infect Dis
Washington D.C., District of Columbia
AIDS Research Consortium of Atlanta
Atlanta, Georgia
AIDS Research Alliance - Chicago
Chicago, Illinois
Louisiana Comm AIDS Rsch Prog / Tulane Univ Med
New Orleans, Louisiana
Louisiana Community AIDS Research Program
New Orleans, Louisiana
Baltimore TRIALS
Baltimore, Maryland
Westat / NICHD
Rockville, Maryland
Comprehensive AIDS Alliance of Detroit
Detroit, Michigan
Wayne State Univ / Univ Hlth Ctr
Detroit, Michigan
Henry Ford Hosp
Detroit, Michigan
Mercer Area Early Intervention Services
Camden, New Jersey
Southern New Jersey AIDS Clinical Trials
Camden, New Jersey
Southern New Jersey AIDS Cln Trials / Dept of Med
Camden, New Jersey
New Jersey Community Research Initiative
Newark, New Jersey
North Jersey Community Research Initiative
Newark, New Jersey
Partners in Research - New Mexico
Albuquerque, New Mexico
Partners Research
Albuquerque, New Mexico
Harlem AIDS Treatment Group / Harlem Hosp Ctr
New York, New York
Harlem AIDS Treatment Group
New York, New York
Portland Veterans Adm Med Ctr / Rsch & Education Grp
Portland, Oregon
The Research and Education Group
Portland, Oregon
Philadelphia FIGHT
Philadelphia, Pennsylvania
Saint Joseph's Hosp
Philadelphia, Pennsylvania
Richmond AIDS Consortium
Richmond, Virginia
Saint Paul's Hosp
Vancouver, British Columbia, Canada
QEII Health Science Centre
Halifax, Nova Scotia, Canada
Saint Joseph's Hosp
London, Ontario, Canada
Ottawa Gen Hosp
Ottawa, Ontario, Canada
Sunnybrook Health Science Centre
Toronto, Ontario, Canada
Toronto Gen Hosp
Toronto, Ontario, Canada
Wellesley Hosp
Toronto, Ontario, Canada
Hotel - Dieu de Montreal
Montreal, Quebec, Canada
Showing 40 of 44 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.